Reduced expression of the membrane skeleton protein beta1-spectrin (SPTBN1) is associated with worsened prognosis in pancreatic cancer.

Spectrins are members of the superfamily of F-actin cross linking proteins that are important as scaffolding proteins for protein sorting, cell adhesion, and migration. In addition, spectrins have been implicated in TGF-beta signaling. The aim of the present study was to analyze the expression and localization of beta1-spectrin (SPTBN1) in pancreatic tissues. mRNA levels of SPTBN1 in cultured pancreatic cancer cell lines, as well as in normal pancreatic tissues (n=18), chronic pancreatitis (n=48) and pancreatic cancer tissues (n=66) were analyzed by real time quantitative RT-PCR. Localization of SPTBN1 in pancreatic tissues was determined by immunohistochemistry. SPTBN1 staining was assessed semi-quantitatively in 55 cancer tissues and survival analysis was carried out using the Kaplan-Meier method. Median SPTBN1 mRNA levels were 6.0-fold higher in pancreatic cancer tissues compared to the normal pancreas (p<0.0001) and 2.2-fold higher compared to chronic pancreatitis tissues (p=0.0002). In the normal pancreas, SPTBN1 was present in the cytoplasm of normal ductal cells and occasionally in pancreatic acinar and centroacinar cells. In pancreatic cancer tissues, SPTBN1 was present in the cytoplasm of pancreatic cancer cells. Low SPTBN1 protein expression indicated a tendency for worsened prognosis with a median survival of 14.0 months, versus 23.8 months for patients whose tumors expressed moderate/high levels of SPTBN1. In conclusion, reduced SPTBN1 expression correlated with shorter survival of pancreatic cancer patients, suggesting a tumor suppressor function of this gene, as has already been shown for other malignancies of the gastrointestinal tract.

[1]  Alfonso Mondragón,et al.  Structures of Two Repeats of Spectrin Suggest Models of Flexibility , 1999, Cell.

[2]  A. Baines,et al.  Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. , 2001, Physiological reviews.

[3]  H. Friess,et al.  The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. , 1999, Oncogene.

[4]  H. Friess,et al.  Approaches to localized pancreatic cancer , 2008, Current oncology reports.

[5]  H. Friess,et al.  Hypothetical Progression Model of Pancreatic Cancer With Origin in the Centroacinar-Acinar Compartment , 2007, Pancreas.

[6]  H. Friess,et al.  Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. , 1999, Pancreas.

[7]  E. Reddy,et al.  Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. , 2005, Cancer research.

[8]  A. Baines.  Evolution of spectrin function in cytoskeletal and membrane networks. , 2009, Biochemical Society transactions.

[9]  Ariel J. Levine,et al.  Identification of elf1, a beta-spectrin, in early mouse liver development. , 1998, The International journal of developmental biology.

[10]  L. Mishra,et al.  Elf3 encodes a novel 200-kD beta-spectrin: role in liver development. , 1999, Oncogene.

[11]  C. Deng,et al.  Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice. , 2003, Science.

[12]  H. Friess,et al.  The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer , 1999, Oncogene.

[13]  R. Urrutia,et al.  Basics of TGF-beta and pancreatic cancer. , 2007, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[14]  R. Urrutia,et al.  Basics of TGF-β and Pancreatic Cancer , 2007, Pancreatology.

[15]  L. Mishra,et al.  Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis , 2008, Hepatology.

[16]  H. Friess,et al.  Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma , 2008, Cancer biology & therapy.

[17]  R. Derynck,et al.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling. , 2003, Nature.

[18]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[19]  Boris Pasche,et al.  TGF-β signaling alterations and susceptibility to colorectal cancer , 2007 .

[20]  J H Hartwig,et al.  Actin-binding proteins 1: spectrin superfamily. , 1994, Protein profile.

[21]  V. Bennett,et al.  Defects in ankyrin-based cellular pathways in metazoan physiology. , 2005, Frontiers in bioscience : a journal and virtual library.

[22]  A. Tannapfel,et al.  Ductal adenocarcinoma of the pancreas , 1992, International journal of pancreatology : official journal of the International Association of Pancreatology.

[23]  L. Mishra,et al.  The role of PRAJA and ELF in TGF-β signaling and gastric cancer , 2005, Cancer biology & therapy.

[24]  L. Mishra,et al.  Elf3 encodes a novel 200-kD β-spectrin: role in liver development , 1999, Oncogene.

[25]  J. Massagué,et al.  Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. , 2003, Nature reviews. Cancer.

[26]  S. Markowitz,et al.  Genetic and epigenetic alterations in colon cancer. , 2002, Annual review of genomics and human genetics.

[27]  Tomas Mitkus,et al.  Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. , 2007, Gastroenterology.

[28]  C. Deng,et al.  Progenitor/stem cells give rise to liver cancer due to aberrant TGF-β and IL-6 signaling , 2008, Proceedings of the National Academy of Sciences.

[29]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[30]  Vincent T. Marchesi,et al.  Erythrocyte spectrin is comprised of many homologous triple helical segments , 1984, Nature.

[31]  J. Massagué,et al.  TGFbeta signaling in growth control, cancer, and heritable disorders. , 2000, Cell.

[32]  Boris Pasche,et al.  TGF-beta signaling alterations and susceptibility to colorectal cancer. , 2007, Human molecular genetics.

[33]  A. Chakrabarti,et al.  Spectrin Organization and Dynamics: New Insights , 2006, Bioscience reports.

[34]  A. Rashid,et al.  Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. , 2007, Oncogene.

[35]  C. Deng,et al.  Disruption of Transforming Growth Factor-β Signaling in ELF β-Spectrin-Deficient Mice , 2003, Science.

[36]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[37]  H. Friess,et al.  Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival , 1993 .

[38]  H. Friess,et al.  Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. , 1999, Biochemical and biophysical research communications.

[39]  H. Friess,et al.  Most Pancreatic Cancer Resections are R1 Resections , 2008, Annals of Surgical Oncology.

[40]  M. Machius,et al.  Localization and Structure of the Ankyrin-binding Site on β2-Spectrin* , 2009, Journal of Biological Chemistry.

[41]  Helmut Friess,et al.  Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. , 2009, Neoplasia.

[42]  A. Rashid,et al.  Inactivation of ELF/TGF-β signaling in human gastrointestinal cancer , 2005, Oncogene.

[43]  L. Mishra,et al.  TGF-beta signaling pathway inactivation and cell cycle deregulation in the development of gastric cancer: role of the beta-spectrin, ELF. , 2006, Biochemical and biophysical research communications.

[44]  H. Friess,et al.  Molecular pathogenesis of pancreatic cancer: advances and challenges. , 2007, Current molecular medicine.

[45]  L. Mishra,et al.  TGF-β signaling pathway inactivation and cell cycle deregulation in the development of gastric cancer: Role of the β-spectrin, ELF , 2006 .

[46]  A. Rashid,et al.  Inactivation of ELF/TGF-beta signaling in human gastrointestinal cancer. , 2005, Oncogene.

[47]  C. Pasquali,et al.  Ductal adenocarcinoma of the body and tail of the pancreas. , 1997, Journal of the American College of Surgeons.

[48]  S B Shohet,et al.  The influence of membrane skeleton on red cell deformability, membrane material properties, and shape. , 1983, Seminars in hematology.

[49]  Ying E. Zhang,et al.  Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.